{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:05Z","timestamp":1793155745711,"version":"4.5.0"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cca.2025.120813","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:05:50Z","timestamp":1767139550000},"page":"120813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Liposomal nano-formulations: advancement in lung cancer treatment"],"prefix":"10.1016","volume":"582","author":[{"given":"Azzalfa","family":"Ashraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qurat ul","family":"Ain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Nisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumaila","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulazim Hussain","family":"Asim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Muhammad","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2025.120813_bb0005","unstructured":"WHO, I.A.f.R.o.C. GCO All Cancers. 2022 04-02-2021]; Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/39-all-cancers-fact-sheet.pdf."},{"key":"10.1016\/j.cca.2025.120813_bb0010","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211034366","article-title":"New approaches and procedures for cancer treatment: current perspectives","volume":"9","author":"Debela","year":"2021","journal-title":"SAGE Open Med."},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00262-021-03013-3","article-title":"Chemotherapy: A double-edged sword in cancer treatment","volume":"71","author":"Behranvand","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.cca.2025.120813_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/or.2022.8405","article-title":"A guide through conventional and modern cancer treatment modalities: A specific focus on glioblastoma cancer therapy","volume":"48","author":"Naser","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cca.2025.120813_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111875","article-title":"Recent advances in regenerative medicine strategies for cancer treatment","volume":"141","author":"Mansouri","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.cca.2025.120813_bb0030","doi-asserted-by":"crossref","first-page":"12567","DOI":"10.1021\/acsnano.1c02103","article-title":"Nanotechnology for boosting cancer immunotherapy and remodeling tumor microenvironment: the horizons in cancer treatment","volume":"15","author":"Gao","year":"2021","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0035","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circul.: Genomic Precis. Med."},{"key":"10.1016\/j.cca.2025.120813_bb0040","series-title":"Nanoformulation Strategies for Cancer Treatment","first-page":"277","article-title":"Formulation and biological stability of nanomedicines in cancer treatment","author":"Bharadwaj","year":"2021"},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0045","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaoncol.2022.5631","article-title":"Emerging strategies for the treatment of small cell lung cancer: a review","volume":"9","author":"Petty","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cca.2025.120813_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.actbio.2020.12.009","article-title":"Clinical applications of nanomedicines in lung cancer treatment","volume":"121","author":"Norouzi","year":"2021","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/acsomega.2c04078","article-title":"Advances in lung cancer treatment using nanomedicines","volume":"8","author":"Sharma","year":"2022","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4068\/cmj.2021.57.1.27","article-title":"Liposomes: biomedical applications","volume":"57","author":"Kim","year":"2021","journal-title":"Chonnam Med. J."},{"issue":"4","key":"10.1016\/j.cca.2025.120813_bb0065","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/molecules27041372","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.cca.2025.120813_bb0070","first-page":"59","article-title":"Liposome and their applications in cancer therapy","author":"Pandey","year":"2016","journal-title":"Braz. Arch. Biol. Technol."},{"issue":"9","key":"10.1016\/j.cca.2025.120813_bb0075","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00432-022-04079-x","article-title":"Liposomal formulations for lung cancer treatment in the last two decades: a systematic review","volume":"148","author":"Canao","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0080","doi-asserted-by":"crossref","first-page":"39066","DOI":"10.1038\/s41598-025-26078-x","article-title":"Preparation of liposomal nanocarriers containing all-trans retinoic acid and docetaxel and their evaluation in a lung cancer cell line","volume":"15","author":"Sinaei","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0085","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1038\/s41467-025-58312-5","article-title":"Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer","volume":"16","author":"Fu","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0090","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/pharmaceutics14030543","article-title":"Methods of liposomes preparation: formation and control factors of versatile Nanocarriers for biomedical and nanomedicine application","volume":"14","author":"Lombardo","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cca.2025.120813_bb0095","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ejmech.2019.01.007","article-title":"Composition design and medical application of liposomes","volume":"164","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cca.2025.120813_bb0100","series-title":"Liposomes: Structure, Composition, Types, and Clinical Applications","author":"Nsairat","year":"2022"},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1166\/jcsb.2012.1020","article-title":"Preparation, characterization and applications of liposomes: state of the art","volume":"1","author":"Laouini","year":"2012","journal-title":"J. Colloid Sci. Biotechnol."},{"key":"10.1016\/j.cca.2025.120813_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115751","article-title":"Liposomes characterization for market approval as pharmaceutical products: analytical methods, guidelines and standardized protocols","volume":"236","author":"Giordani","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.cca.2025.120813_bb0115","doi-asserted-by":"crossref","first-page":"12485","DOI":"10.2147\/IJN.S538382","article-title":"Liposome-based nanoparticle delivery systems for lung diseases: opportunities and challenges","author":"Zhang","year":"2025","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0120","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/pharmaceutics15020706","article-title":"Tailoring the Lamellarity of liposomes prepared by dual centrifugation","volume":"15","author":"Koehler","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/membranes13020135","article-title":"Biomimetic stratum Corneum liposome models: lamellar organization and permeability studies","volume":"13","author":"Roy","year":"2023","journal-title":"Membranes"},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0009-3084(00)00220-6","article-title":"Parameters influencing the determination of liposome lamellarity by 31P-NMR","volume":"109","author":"Fr\u00f6hlich","year":"2001","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.cca.2025.120813_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2019.06.062","article-title":"Evaluation of zeta potential of nanomaterials by electrophoretic light scattering: fast field reversal versus slow field reversal modes","volume":"205","author":"Varenne","year":"2019","journal-title":"Talanta"},{"issue":"24","key":"10.1016\/j.cca.2025.120813_bb0140","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1007\/s00216-017-0527-z","article-title":"Zeta potential: a case study of cationic, anionic, and neutral liposomes","volume":"409","author":"Smith","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.cca.2025.120813_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124799","article-title":"Effects of nanoparticle size, shape, and zeta potential on drug delivery","volume":"666","author":"\u00d6zt\u00fcrk","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.cca.2025.120813_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462688","article-title":"Fast and versatile analysis of liposome encapsulation efficiency by nanoParticle exclusion chromatography","volume":"1662","author":"Bian","year":"2022","journal-title":"J. Chromatogr. A"},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8030025","article-title":"Influence of the encapsulation efficiency and size of liposome on the Oral bioavailability of Griseofulvin-loaded liposomes","volume":"8","author":"Ong","year":"2016","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.cca.2025.120813_bb0160","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1021\/mp400154a","article-title":"Determination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis method","volume":"10","author":"Modi","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.cca.2025.120813_bb0165","article-title":"Gelation of the internal core of liposomes as a strategy for stabilization and modified drug delivery II. Theoretical analysis and modelling of in-vitro release experiments","volume":"585","author":"Petralito","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.cca.2025.120813_bb0170","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijpharm.2016.09.033","article-title":"Comparison of different in vitro release methods used to investigate nanocarriers intended for dermal application","volume":"513","author":"Balzus","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.cca.2025.120813_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122022","article-title":"Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: an update","volume":"624","author":"Sainaga Jyothi","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0180","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ejps.2010.08.010","article-title":"Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: effects of cryoprotectants on structure","volume":"41","author":"Stark","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0185","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.cca.2025.120813_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030543","article-title":"Kiselev methods of liposomes preparation: formation and control factors of versatile Nanocarriers for biomedical and nanomedicine application","volume":"14","author":"Lombardo","year":"2022","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.cca.2025.120813_bb0195","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/17425247.2011.566552","article-title":"Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity","volume":"8","author":"Gubernator","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"issue":"5","key":"10.1016\/j.cca.2025.120813_bb0200","first-page":"26","article-title":"Liposomes-the potential drug carriers","volume":"2","author":"Sirisha","year":"2012","journal-title":"J. Pharm."},{"issue":"4","key":"10.1016\/j.cca.2025.120813_bb0205","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s11095-014-1551-8","article-title":"Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug","volume":"32","author":"Zhang","year":"2015","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0210","first-page":"14","article-title":"Liposome: methods of preparation and applications","volume":"3","author":"Dua","year":"2012","journal-title":"Int. J. Pharm. Stud. Res."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/life12010095","article-title":"Cyclodextrins-in-liposomes: a promising delivery system for lippia sidoides and syzygium aromaticum essential oils","volume":"12","author":"Baldim","year":"2022","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0220","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/21691401.2023.2247036","article-title":"Liposomes for drug delivery: review of vesicular composition, factors affecting drug release and drug loading in liposomes","volume":"51","author":"Pande","year":"2023","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"6","key":"10.1016\/j.cca.2025.120813_bb0225","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1073\/pnas.1324135111","article-title":"Remote loading of preencapsulated drugs into stealth liposomes","volume":"111","author":"Sur","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cca.2025.120813_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Guimar\u00e3es","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.cca.2025.120813_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120051","article-title":"Comprehensive analysis of liposome formulation parameters and their influence on encapsulation, stability and drug release in glibenclamide liposomes","volume":"592","author":"Maritim","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0240","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jconrel.2009.05.036","article-title":"Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties","volume":"139","author":"Zucker","year":"2009","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2012.12.007","article-title":"Key molecular mechanisms in lung cancer invasion and metastasis: A comprehensive review","volume":"87","author":"Perlikos","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0250","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5114\/wo.2021.103829","article-title":"Epidemiology of lung cancer","volume":"25","author":"Thandra","year":"2021","journal-title":"Contemporary Oncology\/Wsp\u00f3\u0142czesna Onkologia"},{"key":"10.1016\/j.cca.2025.120813_bb0255","article-title":"Lung cancer in the world: the incidence, mortality rate and risk factors","volume":"4","author":"Sadeghi-Gandomani","year":"2017","journal-title":"World Cancer Res. J."},{"issue":"6","key":"10.1016\/j.cca.2025.120813_bb0260","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00008469-200012000-00004","article-title":"Diet and lung cancer: a new approach","volume":"9","author":"Ruano-Ravina","year":"2000","journal-title":"Eur. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0265","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann. Glob. Health"},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0270","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1183\/13993003.00359-2016","article-title":"Risk factors for lung cancer worldwide","volume":"48","author":"Malhotra","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.cca.2025.120813_bb0275","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/JTO.0b013e31818020eb","article-title":"The international epidemiology of lung Cancer: geographical distribution and secular trends","volume":"3","author":"Youlden","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cca.2025.120813_bb0280","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.lungcan.2004.07.998","article-title":"Tobacco smoking and cancer: a brief review of recent epidemiological evidence","volume":"45","author":"Sasco","year":"2004","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.cca.2025.120813_bb0285","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1513\/pats.200809-100TH","article-title":"Smoking and lung cancer: the role of inflammation","volume":"5","author":"Walser","year":"2008","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0290","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1378\/chest.65.3.299","article-title":"Clinical manifestations of lung Cancer","volume":"65","author":"Hyde","year":"1974","journal-title":"Chest"},{"issue":"3, Suppl","key":"10.1016\/j.cca.2025.120813_bb0295","doi-asserted-by":"crossref","first-page":"149S","DOI":"10.1378\/chest.07-1358","article-title":"Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd Edition)","volume":"132","author":"Spiro","year":"2007","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.cca.2025.120813_bb0300","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1183\/09031936.04.00113603","article-title":"Lung cancer: clinical presentation and specialist referral time","volume":"24","author":"Buccheri","year":"2004","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0305","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/atm.ATM_276_16","article-title":"Distribution patterns of the metastases of the lung carcinoma in relation to histological type of the primary tumor: an autopsy study","volume":"12","author":"Milovanovic","year":"2017","journal-title":"Ann. Thoracic Med."},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0310","first-page":"189","article-title":"Lung cancer: biology and treatment options. Biochimica et Biophysica Acta (BBA) - reviews on","volume":"1856","author":"Lemjabbar-Alaoui","year":"2015","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.cca.2025.120813_bb0315","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.3390\/ijms22168661","article-title":"Current and future development in lung Cancer diagnosis","volume":"22","author":"Nooreldeen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.cca.2025.120813_bb0320","first-page":"250","article-title":"Lung cancer: diagnosis, treatment principles, and screening","volume":"91","author":"Latimer","year":"2015","journal-title":"Am. Fam. Physician"},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0325","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0147-0272(93)90010-Y","article-title":"Small cell lung cancer: etiology, biology, clinical features, staging, and treatment","volume":"17","author":"Cook","year":"1993","journal-title":"Curr. Probl. Cancer"},{"issue":"1, Supplement","key":"10.1016\/j.cca.2025.120813_bb0330","doi-asserted-by":"crossref","first-page":"259S","DOI":"10.1378\/chest.123.1_suppl.259S","article-title":"Small cell lung Cancer*","volume":"123","author":"Simon","year":"2003","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.cca.2025.120813_bb0335","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung Cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0340","article-title":"ATR-FTIR based pre and post formulation compatibility studies for the Design of Niosomal Drug Delivery System Containing Nonionic Amphiphiles and Chondroprotective Drug","volume":"37","author":"Khan","year":"2015","journal-title":"J. Chem. Soc. Pak."},{"issue":"5","key":"10.1016\/j.cca.2025.120813_bb0345","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jmoldx.2012.03.004","article-title":"Classification of the four Main types of lung Cancer using a MicroRNA-based diagnostic assay","volume":"14","author":"Gilad","year":"2012","journal-title":"J. Mol. Diagn."},{"issue":"49","key":"10.1016\/j.cca.2025.120813_bb0350","article-title":"Lung cancer: current diagnosis and treatment","volume":"106","author":"Hammerschmidt","year":"2009","journal-title":"Dtsch. Arztebl. Int."},{"issue":"4","key":"10.1016\/j.cca.2025.120813_bb0355","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1183\/09031936.02.00280002","article-title":"Diagnostic imaging of lung cancer","volume":"19","author":"Hollings","year":"2002","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.cca.2025.120813_bb0360","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1164\/rccm.200411-1479OC","article-title":"Early lung cancer detection using spiral computed tomography and positron emission tomography","volume":"171","author":"Bastarrika","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"11","key":"10.1016\/j.cca.2025.120813_bb0365","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/JTO.0b013e318158d488","article-title":"Detection of lung cancer by automated sputum cytometry","volume":"2","author":"Kemp","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0370","first-page":"56","article-title":"Lung cancer: diagnosis and management","volume":"75","author":"Collins","year":"2007","journal-title":"Am. Fam. Physician"},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0375","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1164\/rccm.2106153","article-title":"Transbronchial needle aspiration in diagnosing and staging lung cancer: how many aspirates are needed?","volume":"166","author":"Chin","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"Suppl. 4","key":"10.1016\/j.cca.2025.120813_bb0380","first-page":"S304","article-title":"Transthoracic needle biopsy of the lung","volume":"7","author":"DiBardino","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.cca.2025.120813_bb0385","series-title":"Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer","first-page":"123","article-title":"Liposome-based drug delivery for lung cancer","author":"Skupin-Mrugalska","year":"2019"},{"issue":"6","key":"10.1016\/j.cca.2025.120813_bb0390","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/1357-4310(96)88805-8","article-title":"Liposomes as delivery agents for medical imaging","volume":"2","author":"Torchilin","year":"1996","journal-title":"Mol. Med. Today"},{"key":"10.1016\/j.cca.2025.120813_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105576","article-title":"Diagnostic and therapeutic evaluation of folate-targeted paclitaxel and vinorelbine encapsulating theranostic liposomes for non-small cell lung cancer","volume":"156","author":"Karpuz","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.cca.2025.120813_bb0400","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.7150\/thno.15464","article-title":"Recent developments of liposomes as nanocarriers for theranostic applications","volume":"6","author":"Xing","year":"2016","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0405","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.addr.2010.09.003","article-title":"Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects","volume":"63","author":"Maruyama","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.cca.2025.120813_bb0410","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/07357900500359877","article-title":"Phase I clinical trial of topotecan and pegylated liposomal doxorubicin","volume":"23","author":"Garcia","year":"2005","journal-title":"Cancer Investig."},{"key":"10.1016\/j.cca.2025.120813_bb0415","series-title":"Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer","author":"Phase","year":"2003"},{"issue":"8","key":"10.1016\/j.cca.2025.120813_bb0420","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1517\/13543780903114168","article-title":"Clinical overview on Lipoplatin\u2122: a successful liposomal formulation of cisplatin","volume":"18","author":"Boulikas","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"4","key":"10.1016\/j.cca.2025.120813_bb0425","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1023\/A:1011199028318","article-title":"Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer","volume":"12","author":"Harrington","year":"2001","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.cca.2025.120813_bb0430","first-page":"e533","article-title":"Expression of hPNAS-4 radiosensitizes Lewis lung cancer. International journal of radiation oncology* biology*","volume":"84","author":"Zeng","year":"2012","journal-title":"Physics"},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0435","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/1061186X.2014.979829","article-title":"PEGylated VRB plus quinacrine cationic liposomes for treating non-small cell lung cancer","volume":"23","author":"Li","year":"2015","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0440","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23687","article-title":"Victories and deceptions in tumor immunology: Stimuvax(\u00ae)","volume":"2","author":"Kroemer","year":"2013","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0445","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jconrel.2012.09.006","article-title":"Liposomal paclitaxel formulations","volume":"163","author":"Koudelka","year":"2012","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0450","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/molecules23020288","article-title":"Liposomes: clinical applications and potential for image-guided drug delivery","volume":"23","author":"Lamichhane","year":"2018","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.cca.2025.120813_bb0455","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1016\/j.ijrobp.2012.06.028","article-title":"Expression of hPNAS-4 radiosensitizes Lewis lung cancer","volume":"84","author":"Zeng","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"10.1016\/j.cca.2025.120813_bb0460","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1021\/mp400467x","article-title":"Overcoming nonviral gene delivery barriers: perspective and future","volume":"10","author":"Jones","year":"2013","journal-title":"Mol. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.cca.2025.120813_bb0465","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijpharm.2010.01.019","article-title":"Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells","volume":"389","author":"Zou","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0470","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0092-8674(00)80620-0","article-title":"RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals","volume":"101","author":"Zamore","year":"2000","journal-title":"cell"},{"issue":"Suppl. 2","key":"10.1016\/j.cca.2025.120813_bb0475","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000445116","article-title":"Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications","volume":"25","author":"Rudokas","year":"2016","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.cca.2025.120813_bb0480","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jconrel.2015.07.024","article-title":"Nanotechnology approaches for inhalation treatment of lung diseases","volume":"219","author":"Kuzmov","year":"2015","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.cca.2025.120813_bb0485","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.apsb.2012.10.004","article-title":"Preclinical experimental models of drug metabolism and disposition in drug discovery and development","volume":"2","author":"Zhang","year":"2012","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0490","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.lungcan.2009.12.005","article-title":"Lung cancer cell lines: useless artifacts or invaluable tools for medical science?","volume":"68","author":"Gazdar","year":"2010","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.cca.2025.120813_bb0495","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.biomaterials.2011.11.067","article-title":"Liposomal formulations of etoposide and docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines","volume":"33","author":"Jinturkar","year":"2012","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0500","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/pharmaceutics12030206","article-title":"Systematic development and optimization of inhalable Pirfenidone liposomes for non-small cell lung Cancer treatment","volume":"12","author":"Parvathaneni","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0505","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ijpharm.2015.10.020","article-title":"Inhalable liposomal dry powder of gemcitabine-HCl: formulation, in vitro characterization and in vivo studies","volume":"496","author":"Gandhi","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.cca.2025.120813_bb0510","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/jphp.12590","article-title":"TPGS-modified liposomes for the delivery of ginsenoside compound K against non-small cell lung cancer: formulation design and its evaluation in vitro and in vivo","volume":"68","author":"Yang","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0515","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1080\/21691401.2019.1615932","article-title":"Development of R8 modified epirubicin\u2013dihydroartemisinin liposomes for treatment of non-small-cell lung cancer","volume":"47","author":"Liu","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.cca.2025.120813_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111059","article-title":"Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes","volume":"133","author":"Jim\u00e9nez-L\u00f3pez","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cca.2025.120813_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.103506","article-title":"Afatinib liposomal dry powder inhaler: targeted pulmonary delivery of EGFR inhibitor for the management of lung cancer","volume":"74","author":"Vanza","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0530","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2013.02.020","article-title":"Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer","volume":"335","author":"Biswas","year":"2013","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0535","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/10717544.2022.2032872","article-title":"The combination of MnO2@ Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer","volume":"29","author":"Zhang","year":"2022","journal-title":"Drug Deliv."},{"issue":"4","key":"10.1016\/j.cca.2025.120813_bb0540","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1081\/LPR-120016196","article-title":"Liposomal DAUNORUBICIN overcomes drug resistance in human breast, ovarian and lung carcinoma cells","volume":"12","author":"Sadava","year":"2002","journal-title":"J. Liposome Res."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0545","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2014.08.019","article-title":"Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer","volume":"474","author":"Qu","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.cca.2025.120813_bb0550","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.4314\/tjpr.v16i9.6","article-title":"Induction of apoptosis in response to improved gedunin by liposomal nano-encapsulation in human non-small-cell lung cancer (NCI-H292) cell line","volume":"16","author":"Nwokwu","year":"2017","journal-title":"Trop. J. Pharm. Res."},{"issue":"6","key":"10.1016\/j.cca.2025.120813_bb0555","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1248\/bpb.35.975","article-title":"Preparation and <i>in vivo<\/i> evaluation of liposomal Everolimus for lung carcinoma and thyroid carcinoma","volume":"35","author":"Iwase","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.cca.2025.120813_bb0560","first-page":"1","article-title":"Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation","author":"Sawant","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.cca.2025.120813_bb0565","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1590\/S0100-879X2006005000125","article-title":"Preparation and cytotoxicity of cisplatin-containing liposomes","volume":"40","author":"Carvalho J\u00fanior","year":"2007","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"6","key":"10.1016\/j.cca.2025.120813_bb0570","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/00914037.2017.1332624","article-title":"Carboplatin liposomal nanoparticles: preparation, characterization, and cytotoxicity effects on lung cancer in vitro environment","volume":"67","author":"Poy","year":"2018","journal-title":"Int. J. Polym. Mater. Polym. Biomater."},{"issue":"12","key":"10.1016\/j.cca.2025.120813_bb0575","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202000110","article-title":"Best practices for preclinical in vivo testing of cancer nanomedicines","volume":"9","author":"Valcourt","year":"2020","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.cca.2025.120813_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123703","article-title":"Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer","volume":"650","author":"Korucu Aktas","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.cca.2025.120813_bb0585","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1007\/s13346-021-01088-0","article-title":"Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation","volume":"12","author":"Sawant","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"10","key":"10.1016\/j.cca.2025.120813_bb0590","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3390\/pharmaceutics12100939","article-title":"Development of liposomal vesicles for Osimertinib delivery to EGFR mutation\u2014positive lung Cancer cells","volume":"12","author":"Skupin-Mrugalska","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cca.2025.120813_bb0595","series-title":"Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy","first-page":"1","article-title":"Chapter 1 - EGFR and HER2 inhibitors as sensitizing agents for cancer chemotherapy","author":"Barbuti","year":"2019"},{"key":"10.1016\/j.cca.2025.120813_bb0600","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.molliq.2018.03.024","article-title":"A novel pH-sensitive liposome to trigger delivery of afatinib to cancer cells: impact on lung cancer therapy","volume":"259","author":"Almurshedi","year":"2018","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.cca.2025.120813_bb0605","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijpharm.2019.02.001","article-title":"Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer","volume":"560","author":"Lu","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"null","key":"10.1016\/j.cca.2025.120813_bb0610","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/IJN.S53310","article-title":"GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation","volume":"9","author":"Cheng","year":"2014","journal-title":"Int. J. Nanomedicine"},{"issue":"8","key":"10.1016\/j.cca.2025.120813_bb0615","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.7150\/thno.72594","article-title":"Antibody-based drug delivery systems for cancer therapy: mechanisms, challenges, and prospects","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.cca.2025.120813_bb0620","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cbdd.12786","article-title":"Preparation, characterization, and cytotoxic effects of liposomal nanoparticles containing cisplatin: an in vitro study","volume":"88","author":"Poy","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0625","first-page":"1168","article-title":"Comparative of in-vitro evaluation between Erlotinib loaded nanostructured lipid carriers and liposomes against A549 lung Cancer cell line","volume":"18","author":"Abedi Gaballu","year":"2019","journal-title":"Iran. J. Pharm. Res."},{"issue":"26","key":"10.1016\/j.cca.2025.120813_bb0630","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2217\/nnm-2020-0169","article-title":"Optimization and efficacy study of synergistic vincristine coloaded liposomal doxorubicin against breast and lung cancer","volume":"15","author":"Ghosh","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.cca.2025.120813_bb0635","article-title":"Synergistic co-loading of vincristine improved chemotherapeutic potential of pegylated liposomal doxorubicin against triple negative breast cancer and non-small cell lung cancer","volume":"31","author":"Ghosh","year":"2021","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0640","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12668-022-00938-6","article-title":"Preparation and evaluation of Gefitinib containing Nanoliposomal formulation for lung Cancer therapy","volume":"12","author":"Rohilla","year":"2022","journal-title":"BioNanoScience"},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0645","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40199-020-00374-5","article-title":"Development, optimization and in vitro evaluation of oxaliplatin loaded nanoparticles in non-small cell lung cancer","volume":"28","author":"Esim","year":"2020","journal-title":"DARU J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.cca.2025.120813_bb0650","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1080\/02726351.2021.1906367","article-title":"Investigation of sorafenib tosylate loaded liposomal dry powder inhaler for the treatment of non-small cell lung cancer","volume":"39","author":"Patel","year":"2021","journal-title":"Part. Sci. Technol."},{"key":"10.1016\/j.cca.2025.120813_bb0655","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.2147\/IJN.S170035","article-title":"Iridium (III) complex-loaded liposomes as a drug delivery system for lung cancer through mitochondrial dysfunction","author":"Liao","year":"2018","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0660","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/jamp.2009.0794","article-title":"Formulations for pulmonary administration of anticancer agents to treat lung malignancies","volume":"24","author":"Carvalho","year":"2011","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0665","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11095-008-9755-4","article-title":"Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug","volume":"26","author":"Garbuzenko","year":"2009","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.cca.2025.120813_bb0670","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4155\/tde.13.71","article-title":"Liposomal formulations for inhalation","volume":"4","author":"Cipolla","year":"2013","journal-title":"Ther. Deliv."},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0675","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.apsb.2018.03.004","article-title":"Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers","volume":"8","author":"Zhang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.cca.2025.120813_bb0680","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2174\/1381612823666161116114732","article-title":"Liposomes for pulmonary drug delivery: the role of formulation and inhalation device design","volume":"23","author":"Elhissi","year":"2017","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.cca.2025.120813_bb0685","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.currproblcancer.2017.07.002","article-title":"Risk factors of lung Cancer in nonsmoker","volume":"41","author":"Akhtar","year":"2017","journal-title":"Curr. Probl. Cancer"},{"issue":"6","key":"10.1016\/j.cca.2025.120813_bb0690","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/jps.1023","article-title":"Trends and developments in liposome drug delivery systems","volume":"90","author":"Lian","year":"2001","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.cca.2025.120813_bb0695","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3923\/pjbs.2006.1181.1191","article-title":"Liposome as a carrier for advanced drug delivery","volume":"9","author":"Shaheen","year":"2006","journal-title":"Pak. J. Biol. Sci."},{"key":"10.1016\/j.cca.2025.120813_bb0700","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cbi.2017.09.006","article-title":"Safety of novel liposomal drugs for cancer treatment: advances and prospects","volume":"295","author":"He","year":"2018","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0705","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/01902149309071077","article-title":"Pulmonary effects of chronic exposure to liposome aerosols in mice","volume":"19","author":"Myers","year":"1993","journal-title":"Exp. Lung Res."},{"issue":"1\u20133","key":"10.1016\/j.cca.2025.120813_bb0710","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0378-5173(92)90242-T","article-title":"Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep","volume":"87","author":"Schreier","year":"1992","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0715","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1152\/jappl.1994.77.1.415","article-title":"No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes","volume":"77","author":"Canonico","year":"1994","journal-title":"J. Appl. Physiol."},{"issue":"7","key":"10.1016\/j.cca.2025.120813_bb0720","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00001813-200008000-00006","article-title":"Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial","volume":"11","author":"Skubitz","year":"2000","journal-title":"Anti-Cancer Drugs"},{"issue":"11","key":"10.1016\/j.cca.2025.120813_bb0725","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1111\/j.1600-6143.2006.01529.x","article-title":"Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients","volume":"6","author":"Corcoran","year":"2006","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0730","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1359-0294(00)00090-X","article-title":"Liposome application: problems and prospects","volume":"6","author":"Barenholz","year":"2001","journal-title":"Curr. Opin. Colloid Interface Sci."},{"issue":"1","key":"10.1016\/j.cca.2025.120813_bb0735","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/21691401.2014.953633","article-title":"Application of liposomes in medicine and drug delivery","volume":"44","author":"Daraee","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"4","key":"10.1016\/j.cca.2025.120813_bb0740","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40005-016-0260-1","article-title":"Liposomal drug delivery system","volume":"46","author":"Kim","year":"2016","journal-title":"J. Pharm. Investig."},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0745","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0378-5173(97)00135-X","article-title":"Liposomes in drug delivery: Progress and limitations","volume":"154","author":"Sharma","year":"1997","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.cca.2025.120813_bb0750","doi-asserted-by":"crossref","first-page":"13039","DOI":"10.2147\/IJN.S554821","article-title":"Bridging the gap: the role of advanced formulation strategies in the clinical translation of nanoparticle-based drug delivery systems","author":"Herdiana","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.cca.2025.120813_bb0755","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2025.1002339","article-title":"Engineered nanocarriers for targeted lung cancer therapy: mechanistic innovations and recent clinical progress","volume":"6","author":"Lee","year":"2025","journal-title":"Explor. Target. Anti-tumor Ther."},{"issue":"9","key":"10.1016\/j.cca.2025.120813_bb0760","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/pharmaceutics17091091","article-title":"Polymeric nanoparticles for targeted lung cancer treatment: review and perspectives","volume":"17","author":"Kapoor","year":"2025","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.cca.2025.120813_bb0765","doi-asserted-by":"crossref","first-page":"151","DOI":"10.15171\/apb.2015.022","article-title":"Solid lipid nanoparticles as efficient drug and gene delivery systems: recent breakthroughs","volume":"5","author":"Dolatabadi","year":"2015","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.cca.2025.120813_bb0770","series-title":"Nanotechnology-Based Targeted Drug Delivery Systems for Lung cancer","first-page":"95","article-title":"Solid lipid nanoparticle-based drug delivery for lung cancer","author":"Abdelaziz","year":"2019"},{"issue":"15","key":"10.1016\/j.cca.2025.120813_bb0775","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/jnci\/90.15.1130","article-title":"Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes","volume":"90","author":"Zou","year":"1998","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125006928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125006928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T08:57:29Z","timestamp":1772355449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125006928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":155,"alternative-id":["S0009898125006928"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120813","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomal nano-formulations: advancement in lung cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120813","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120813"}}